Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.
In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis. However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease. The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases.
Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.
- ^ a b Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrob Agents Chemother. 51 (3): 1096–8. doi:10.1128/AAC.01366-06. PMC 1803157 . PMID 17194822. Free full text.
- ^ Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Trop. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
- ^ "New drug shows promise against Asian liver fluke". 2010-11-24.